Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin relapse prophylaxis after allogeneic HSCT in high-risk B-cell precursor acute lymphoblastic leukemia
2026-525964-17-00Phase 2Authorised
- Sponsor
- PETHEMA
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by PETHEMA. Primary endpoints: Relapse rate, Cumulative incidence of relapse and 1 more. Planned start Sep 2026; status: authorised.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2026-525964-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525964-17-00.